

focus group testing, with additional variations informed by, among other things, focus group results (see https://www.reginfo.gov/public/do/PRAViewIC?ref_nbr=202008-0910-021&icID=253321 for information about FDA’s front-of-pack focus groups, including graphic FOP schemes tested). The study will be a controlled, randomized experiment that will use a 15-minute web-based questionnaire to collect information from 3,000 U.S. adult members of an online consumer panel maintained by a contractor. The sample will be balanced to reflect the U.S. Census on gender, education, age, and ethnicity/race. A measure of nutrition literacy will also be used to balance the sample to ensure a variety of literacy levels for each condition.

Conditions for the study will be: (1) a set of draft FOP schemes, including “no-scheme” controls; (2) three types of mock food products (i.e., a breakfast cereal, a frozen meal, and a canned soup); and (3) a “no-information” condition where no explanation of the FOP scheme is provided. Each participant will be randomly assigned to a condition, which will include viewing a label image and responding to various measures of the label’s effectiveness. Some assignments may include making a choice between two label images. Product perceptions (e.g., healthfulness and contribution to a healthy diet), label perceptions (e.g., believability, trustworthiness, and effects perceptions), and purchase/choice questions will constitute the measures of response in the experiment. The

instrument will also collect information from participants about their history of purchasing or consuming similar products, nutrition knowledge, dietary interests, motivation regarding label use, health status, and demographic characteristics.

The studies are part of our continuing effort to help enable consumers to make informed dietary choices and construct healthful diets. We intend to use the results to inform our continued exploration of an FOP labeling scheme. We will not use the results to develop population estimates.

Description of Respondents: Respondents to this collection of information include members of the general public.

FDA estimates the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN ¹

Activity	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
Experiment Pretest 1	180	1	180	0.25 (15 minutes) ..	45
Experiment Pretest 2	25	1	25	0.25 (15 minutes) ..	6
Experiment	3,000	1	3,000	0.25 (15 minutes) ..	750
Total					801

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

Dated: January 23, 2023.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2023–01551 Filed 1–25–23; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Statement of Organization, Functions, and Delegations of Authority

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA), Office of Operations (OO), Office of Talent Solutions (OTS) has modified its structure, and the Office of FDA Commissioned Corps (OFCC) was established. These new organizational structures were approved by the Deputy Secretary of Health and Human Services on September, 26, 2022, and effective on November, 2, 2022.

FOR FURTHER INFORMATION CONTACT: Tiffany Branch, Associate Director for Management, Office of Enterprise Management Services, Office of

Operations, Food and Drug Administration, 3 White Flint North, 11601 Landsdown Street, North Bethesda, MD 20852, 240–402–3156.

SUPPLEMENTARY INFORMATION:

I. Introduction

Part D, Chapter D–B, (Food and Drug Administration), the Statement of Organization, Functions and Delegations of Authority for the Department of Health and Human Services (35 FR 3685, February 25, 1970, 64 FR 56606, November 9, 1995, 64 FR 36361, July 6, 1999, 72 FR 50112, August 30, 2007, 74 FR 41713, August 18, 2009, 76 FR 45270, July 28, 2011, and 84 FR 22854, May 20, 2019) is amended to reflect the reorganization of the OO, OTS and establishment of OO, OFCC.

This reorganization established the OO, OFCC. In the OTS immediate office realigned the Commissioned Corps Staff (CCS) functions and resources to OO, OFCC; established the Business Operations Staff; retitled the Policy and Accountability Staff to Policy, Programs, and Accountability Staff; and abolished the CCS.

In the Division of Talent Services, I (DTS I) retitled the division to Division of Talent Solutions I (DTS I); retitled the

CDER Branch 1 to Recruitment and Staffing Branch 1; retitled the CDER Branch 2 to Recruitment and Staffing Branch 2; retitled the CDER Branch 3 to Recruitment and Staffing Branch 3 (RSB3); established the Recruitment and Staffing Branch 4; and established the Special Pay and Hiring Branch.

In the Division of Talent Services II (DTS II) retitled the division to Division of Talent Solutions II (DTS II); retitled the CFSAN and CVM Branch to Recruitment and Staffing Branch 5; retitled OC and NCTR Branch to Recruitment and Staffing Branch 6; retitled the OO Branch to Recruitment and Staffing Branch 7; established the Classification Branch 1; and established the Classification Branch 2.

In the Division of Talent Services III (DTS III) retitled the division to Division of Talent Solutions III (DTS III); realigned the CBER Branch functions and resources to DTS I/RSB3; realigned the CDRH Branch functions and resources to DTS II and retitled as Recruitment and Staffing Branch 8; realigned the CTP Branch functions and resources to DTS II and retitled as Recruitment and Staffing Branch 9; established the OTS/DTS III/Data Quality Branch 2; established the Data

Quality Branch 3; and established Data Quality Branch 4.

In the Division of Talent Services IV (DTS IV) realigned the ORA Branch 1 functions to DTS III and retitled as the Recruitment and Staffing Branch 10; realigned the ORA Branch 2 functions to DTS III and retitled as the Recruitment and Staffing Branch 11; and abolished DTS IV.

In the Division of Talent Sourcing and Staffing (DTSS) realigned the Corporate Recruitment and Title 38 Branch functions and resources to the OTS Immediate Office Executive Resources Staff and retitled as the Scientific Programs and Executive Resources Staff; realigned the Scientific Staffing and Outreach Branch functions and resources to the OTS Immediate Office Scientific Talent Recruitment Staff and retitled as the Science, Technology, Engineering, and Mathematics Outreach Staff; realigned the Customer Care and Data Quality Branch functions and resources to DTS III and retitled as the Data Quality Branch 1; and abolished DTSS.

Under Part D, FDA, OO, OTS has been restructured as follows:

DCNJ. ORGANIZATION. The Office of Talent Solutions is headed by the FDA Chief Talent Officer and includes the following organizational units:

Business Operations Staff
Policy, Programs, and Accountability Staff
Scientific Programs and Executive Resources Staff
Science, Technology, Engineering, and Mathematics Outreach Staff
Division of Talent Solutions I
Recruitment and Staffing Branch 1
Recruitment and Staffing Branch 2
Recruitment and Staffing Branch 3
Recruitment and Staffing Branch 4
Special Hiring and Pay Branch
Division of Talent Solutions II
Recruitment and Staffing Branch 5
Recruitment and Staffing Branch 6
Recruitment and Staffing Branch 7
Recruitment and Staffing Branch 8
Recruitment and Staffing Branch 9
Classification Branch 1
Classification Branch 2
Division of Talent Solutions III
Recruitment and Staffing Branch 10
Recruitment and Staffing Branch 11
Delegated Examining Branch
Data Quality Branch 1
Data Quality Branch 2
Data Quality Branch 3
Data Quality Branch 4

Under Part D, FDA, OO has been restructured as follows:

DCNK. ORGANIZATION. The Office of FDA Commissioned Corps (OFCC) is headed by the Director of FDA Commissioned Corps.

II. Delegations of Authority

Pending further delegation, directives, or orders by the Commissioner of Food and Drugs, all delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegations, provided they are consistent with this reorganization.

III. Electronic Access

This reorganization is reflected in FDA's Staff Manual Guide (SMG). Persons interested in seeing the complete SMG can find it on FDA's website at: <http://www.fda.gov/AboutFDA/ReportsManualsForms/StaffManualGuides/default.htm> (Authority: 44 U.S.C. 3101.)

Xavier Becerra,

Secretary of Health and Human Services.
[FR Doc. 2023-01567 Filed 1-25-23; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Statement of Organization, Functions, and Delegations of Authority

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA), Office of Operations (OO), Office of Enterprise Management Services (OEMS) has modified its structure. This new organizational structure was approved by the Deputy Secretary of Health and Human Services on September 26, 2022, and effective on September 26, 2022.

FOR FURTHER INFORMATION CONTACT: Tiffany Branch, Associate Director for Management, Office of Enterprise Management Services, Office of Operations, Food and Drug Administration, 3 White Flint North, 11601 Landsdown Street, North Rockville, MD 20852, 240-402-3156.

SUPPLEMENTARY INFORMATION:

I. Introduction

Part D, Chapter D-B, (Food and Drug Administration), the Statement of Organization, Functions and Delegations of Authority for the Department of Health and Human Services (35 FR 3685, February 25, 1970, 60 FR 56606, November 9, 1995, 64 FR 36361, July 6, 1999, 72 FR 50112, August 30, 2007, 74 FR 41713, August

18, 2009, 76 FR 45270, July 28, 2011, and 84 FR 22854, May 20, 2019) is amended to reflect reorganization of OEMS.

This reorganization realigned the FDA History Office function from the Office of the Commissioner (OC), Office of External Affairs (OEA) to OO, OEMS and revised the OEA and OEMS functional statements to this function realignment.

The Food and Drug Administration, Office of Operations, Office of Enterprise Management Services has been restructured as follows:

DCNA. ORGANIZATION. OEMS is headed by the Director of Enterprise Management Services and includes the following organizational units:
Division of Compliance and Conflict Prevention
Division of Human Capital
Division of Information Governance
FDA History Office
Division of Resources Management
Division of Vendor Management

II. Delegations of Authority

Pending further delegation, directives, or orders by the Commissioner of Food and Drugs, all delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegations, provided they are consistent with this reorganization.

III. Electronic Access

This reorganization is reflected in FDA's Staff Manual Guide (SMG). Persons interested in seeing the complete SMG can find it on FDA's website at: <https://www.fda.gov/AboutFDA/ReportsManualsForms/StaffManualGuides/default.htm>. (Authority: 44 U.S.C. 3101.)

Xavier Becerra,

Secretary of Health and Human Services.
[FR Doc. 2023-01566 Filed 1-25-23; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-N-2174]

Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments.